What were the key takeaways from Bruker’s earnings call?

Did Bruker beat or miss consensus estimates last quarter?

What is Bruker's latest dividend and current dividend yield?

What guidance did Bruker's management provide for the next earnings period?

What were the key takeaways from Bruker's earnings call?

What is Bruker's gross profit margin?

What factors drove the changes in Bruker's revenue and profit?

What does Bruker do and what are its main business segments?

- **Q3 Revenue Resilience**: $860.5 million with organic decline of 4.5%, but bookings growth and book-to-bill >1.0 signal improving demand.
- **ACA/GOV Recovery**: Mid-teens order growth outside the U.S., with Europe, Japan, and China leading.
- **Cost Savings Drive Growth**: $120 million cost-down target to enable double-digit EPS growth in 2026, despite 4-5% organic revenue decline in 2025.
- **Strategic Initiatives**: Spatial biology, diagnostics (ELITech), and applied markets (security detection) are key growth engines.

**【CEO Summary Section】**
- Q3 2025 revenue was $860.5 million, down 0.5% YoY, with organic revenue declining 4.5% due to weaker ACA/GOV demand. However, bookings showed mid-single-digit growth, driven by ACA/GOV orders outside the U.S. and strong biopharma demand.
- ACA/GOV orders grew mid-teens YoY organically, with Europe, Japan, and China offsetting U.S. weakness. Biopharma bookings were the strongest segment, and China showed early signs of stimulus funding.
- The company expects $100-120 million in cost savings by 2026, targeting double-digit EPS growth and margin expansion. Q4 guidance is conservative due to delayed installations and site readiness issues.

**【CFO Financial Commentary】**
- Q3 non-GAAP EPS was $0.45, down 25% YoY but up sequentially from $0.32 in Q2. Full-year 2025 guidance: revenue $3.41-3.44 billion (1-2% growth), organic revenue decline 4-5%, and non-GAAP EPS $1.85-1.90.
- Operating margin expected to decline 250bps YoY due to M&A, tariffs, and FX headwinds. The mandatory convertible preferred offering will dilute EPS by $0.20 in 2026.

**【Q&A Key Highlights】**
- **Order Momentum**: Book-to-bill >1.0 in Scientific Instruments, with ACA/GOV orders improving outside the U.S. and biopharma strength. China showed $6 million in stimulus-related orders.
- **Government Shutdown Impact**: Potential delays in Q4 orders, but guidance assumes minimal impact.
- **2026 Outlook**: CEO confident in margin expansion and double-digit EPS growth, despite uncertain ACA/GOV demand. Diagnostics (ELITech) and applied markets (security detection) are key growth areas.
- **Cost Savings**: CFO confirms $120 million cost-down target, with 95% of initiatives underway. Margin expansion will occur even in flat revenue scenarios.

Bruker Corporation (BRKR) Q3 2025 Earnings Call Transcript

- **Cost Savings Ambition**: $100M-$120M annualized cuts for FY26, targeting 300+ bps margin expansion.
- **Revenue Outlook**: FY25 organic decline 2%-4%, FY26 cautious for partial recovery with double-digit EPS growth.
- **Tariff Mitigation**: Shifting production to EU/U.S. if Swiss tariffs exceed 15%; modeling 39% as worst-case scenario.
- **Q2 Results**: Non-GAAP EPS $0.32 (-39% YoY), driven by tariffs, FX, and weak demand.
- **Key Growth Drivers**: Spatial biology, semiconductor metrology, and microbiology diagnostics.

**【CEO Summary Section】**
- **Revenue Challenges**: Q2 organic revenue declined 7.0% YoY, driven by U.S. academic funding delays and China stimulus delays. Book-to-bill ratio was mid-0.9 range.
- **Cost Savings Initiative**: Announced $100M-$120M annualized cost reductions for FY26, targeting 300+ bps margin improvement even in flat growth scenarios.
- **Tariffs Impact**: U.S. tariffs on Swiss imports (potential 39%) could affect supply chain; planning to shift production to EU/U.S. factories if needed.
- **Innovation Focus**: Emphasized next-gen disease research tools, AI-driven semiconductor metrology, and microbiology diagnostics as growth drivers.
- **FY26 Outlook**: Cautiously optimistic for partial recovery; aiming for double-digit EPS growth via cost cuts, regardless of market recovery.

**【CFO Financial Commentary】**
- **Q2 Results**: Reported revenue $797.4M (-0.4% YoY), organic down 7.0%. Non-GAAP EPS $0.32 (-39% YoY), impacted by tariffs, FX, and lower volumes.
- **FY25 Guidance**: Organic revenue decline 2%-4%, constant exchange rate growth 0.5%. Non-GAAP EPS $1.95-$2.05 (-15% to -19% YoY).
- **Cash Flow**: Q2 free cash outflow $110M due to tax payments; FY25 operating cash flow expected to improve with cost savings ($30M in FY25, $90M+ in FY26).
- **Margins**: Q2 non-GAAP operating margin 9.0% (-480bps YoY). FY25 operating margin decline 210bps, driven by tariffs, FX, and organic weakness.

**【Q&A Key Highlights】**
- **Backlog & Recovery**: Backlog 6.5 months (down from 7.0); FY26 recovery hinges on U.S. funding clarity. Q3 organic revenue expected mid-single-digit decline, Q4 modest improvement.
- **Tariff Strategy**: Modeling Swiss tariffs at 15%; worst-case 39% would shift production to EU/U.S. factories.
- **China Stimulus**: Soft tender activity in Q2; customers optimistic for stimulus release in H2.
- **Cost Savings Execution**: $30M FY25 savings (mostly Q4), $90M+ FY26. No plans to reverse cuts even if top line recovers.
- **Leverage & Debt**: Target leverage ~2.7x; compliant with 3.5x covenant. No immediate plans for share buybacks.


Bruker Corporation (BRKR) Q2 2025 Earnings Call Transcript

- **Q1 Strong Execution**: 11% revenue growth, 12.5% CER growth, 5.1% BSI organic growth.
- **Headwinds Mitigated**: $90M ACA/GOV & tariff headwinds offset by $45M actions by 2026.
- **AI & Semicon Growth**: TSMC orders strong, AI tools booked for 2026 delivery.
- **China Uncertainty**: Stimulus delays, <10% of revenue at risk, MRI market weak.
- **FY25 Guidance**: Flat EPS (-5% YoY ex-currency), 2026 margin expansion resume.

**【CEO Business Overview】**
- Q1 2025 reported revenue: $801.4M (+11% YoY), CER growth 12.5% YoY, driven by 5.1% organic growth in BSI segment.
- Key product launches: Spatial biology (GeoMx, CosMx), molecular diagnostics (RECIPE acquisition), and NMR systems.
- ACA/GOV headwinds: U.S. ACA/GOV revenue expected to decline 20-25% YoY, China stimulus delays.
- Tariff mitigation: $90M gross headwind offset by $45M through pricing, cost cuts, and supply chain re-engineering by 2026.

**【CFO Financial Details】**
- Q1 2025 non-GAAP EPS: $0.47 (-11.3% YoY) due to FX headwinds.
- FY 2025 guidance: Revenue $3.48B-$3.55B (+3.5-5.5% YoY), non-GAAP EPS $2.40-$2.48 (0-3% YoY growth).
- Operating margin: Flat YoY with >70bps organic improvement offset by M&A and FX dilution.

**【Q&A Key Takeaways】**
- **Tariff Impact**: China delays U.S. imports with 125% tariffs, U.S. imports from EU/Malaysia face 10% tariffs, total $40M op margin headwind.
- **Order Trends**: BSI book-to-bill 0.95, ACA/GOV orders weak in U.S. and China, biopharma and semicon strong.
- **China Stimulus**: $<10M revenue in Q1, likely 2026 impact; superconducting MRI market weak.
- **AI & Semicon**: TSMC remains largest customer, AI-driven bookings strong with long delivery times.

Bruker (BRKR)-7 May 25-2025 Q1 Earnings call transcript

- **2024 Growth**: 14% CER revenue, 4% organic growth, fueled by BSI segment (4.2% growth) and strategic acquisitions.
- **2025 Outlook**: 5-7% CER revenue growth, 11-13% EPS growth, 140bps margin expansion.
- **Key Drivers**: Semiconductor metrology (20%+ Q4 growth), microbiology diagnostics, China stimulus (~$15M in 2024).
- **Risks**: NIH funding uncertainty (3-4% organic growth target includes 8% cut scenario), biopharma recovery gradual.
- **Margin Focus**: 140bps operating margin expansion via cost control and M&A integration.

**【CEO Business Overview】**
- **2024 Fiscal Year Highlights**: Constant exchange rate (CER) revenue grew 14%, with 4% organic growth, driven by strong performance in Scientific Instruments (BSI) and BEST segments. Key acquisitions (e.g., ELITech, NanoString) expanded into spatial biology, molecular diagnostics, and lab automation.
- **2025 Guidance**: 
  - CER revenue growth of 5-7% (3-4% organic + 2-3% M&A contribution)
  - Non-GAAP EPS growth of 11-13% (14-16% CER growth)
  - Operating margin expansion of 140bps to 16.8%.
- **Key Growth Drivers**: Semiconductor metrology (20%+ Q4 growth), microbiology diagnostics, and China stimulus orders (~$15M in H2 2024). Biopharma recovery expected to accelerate in H2 2025.

**【CFO Financial Highlights】**
- **Q4 2024 Results**: 
  - Revenue: $979.6M (+14.6% YoY, 15.8% CER)
  - Non-GAAP EPS: $0.76 (+8.6% YoY)
  - Operating margin: 18.1% (matching Q4 2023)
- **Full Year 2024**: 
  - Revenue: $3.37B (+13.6% YoY)
  - Free cash flow: $134M (down 109% YoY due to M&A expenses)
- **2025 Outlook**: 
  - Reported revenue: $3.47-3.54B (+3-5% YoY)
  - First quarter organic growth flat YoY, with margin improvement accelerating in Q2+.

**【Q&A Key Takeaways】**
- **NIH Uncertainty**: 3-4% organic growth target baked in 8% NIH funding cut scenario; Europe/China stimulus offsetting U.S. weakness.
- **China Stimulus**: ~$15M orders in H2 2024, with more expected in 2025; revenue impact spread across 2025-2026.
- **Semiconductor Metrology**: 20%+ Q4 growth, $250M+ annual revenue (~$125M from AI/HPC tools).
- **Biopharma Recovery**: Gradual, with stronger momentum expected in H2 2025.
- **Margin Expansion**: 140bps YoY improvement driven by operational excellence and M&A synergies.

BRKR

BRKR fundamentals

Earnings Call

You can ask Aime